US Antidiabetics Drug Market Outlook 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“US Antidiabetics Drug Market Outlook 2022” report gives clinical and non-clinical insight on trends associated with the development of Antidiabetics drug market in US. Report helps to identify the diabetes epidemiology ( Prevalence of Type 1 & 2 Diabetes) in the US market along with the associated economic burden and productivity loss.
Diabetes rates in the US have been increasing substantially. While the number of people with diabetes in the US continues to grow, the number of new cases has been declining since 2009, after decades of increases in new cases. Although the numbers are not growing dramatically each year, they are still alarmingly high. About 8.1 Million people with diabetes do not have knowledge that they have diabetes as prediabetes and type2 diabetes have few physical symptoms.
Diabetes mellitus being the most common chronic disease with high mortality, morbidity and costs, the number of people with diabetes is still increasing in US and other countries. More than 29 million Americans are living with diabetes, and 86 million are living with prediabetes. Though the benefits of tight control of blood glucose have been well recognized still the management of diabetes is complex which demands for the more efficient standardized antidiabetic regimen.
US insulin market occupies more than 70% of the overall insulin market and is expected to grow significantly until 2022 owing to the growing number of individuals with diabetes. Factors such as better accessibility to treatment therapies and favorable reimbursement programs will result in the high turnout of patients opting for diabetes treatment, which in turn will boost the market’s growth prospects in this region.
The US Antidiabetics Drug Market has seen a resurgence of activity in recent years with promising new products, such as ultra-rapid-acting and liver targeted insulin analogues, and insulin plus GLP-1 combinations in late stage development. Earlier stage candidates include several oral formulations, as well as ultra-long acting insulin analogues. Some ultra-long acting insulin analogues in development have the potential to greatly reduce the dosing frequency to just once weekly for basal insulin needs, as opposed to once daily.
In addition, the prospect of promising drugs in the pipeline, along with increasing awareness, is expected to contribute to the market's growth during the forecast period. The market is dominated by three key players: Eli Lilly, Novo Nordisk, and Sanofi. Novo Nordisk is the major vendor in the global insulin market. The largest product wise market revenue was generated by Lantus, which is marketed by Sanofi.
“US Antidiabetics Drug Market Outlook 2022” report highlights:
“US Antidiabetics Drug Market Outlook 2022” report gives clinical and non-clinical insight on trends associated with the development of Antidiabetics drug market in US. Report helps to identify the diabetes epidemiology ( Prevalence of Type 1 & 2 Diabetes) in the US market along with the associated economic burden and productivity loss.
Diabetes rates in the US have been increasing substantially. While the number of people with diabetes in the US continues to grow, the number of new cases has been declining since 2009, after decades of increases in new cases. Although the numbers are not growing dramatically each year, they are still alarmingly high. About 8.1 Million people with diabetes do not have knowledge that they have diabetes as prediabetes and type2 diabetes have few physical symptoms.
Diabetes mellitus being the most common chronic disease with high mortality, morbidity and costs, the number of people with diabetes is still increasing in US and other countries. More than 29 million Americans are living with diabetes, and 86 million are living with prediabetes. Though the benefits of tight control of blood glucose have been well recognized still the management of diabetes is complex which demands for the more efficient standardized antidiabetic regimen.
US insulin market occupies more than 70% of the overall insulin market and is expected to grow significantly until 2022 owing to the growing number of individuals with diabetes. Factors such as better accessibility to treatment therapies and favorable reimbursement programs will result in the high turnout of patients opting for diabetes treatment, which in turn will boost the market’s growth prospects in this region.
The US Antidiabetics Drug Market has seen a resurgence of activity in recent years with promising new products, such as ultra-rapid-acting and liver targeted insulin analogues, and insulin plus GLP-1 combinations in late stage development. Earlier stage candidates include several oral formulations, as well as ultra-long acting insulin analogues. Some ultra-long acting insulin analogues in development have the potential to greatly reduce the dosing frequency to just once weekly for basal insulin needs, as opposed to once daily.
In addition, the prospect of promising drugs in the pipeline, along with increasing awareness, is expected to contribute to the market's growth during the forecast period. The market is dominated by three key players: Eli Lilly, Novo Nordisk, and Sanofi. Novo Nordisk is the major vendor in the global insulin market. The largest product wise market revenue was generated by Lantus, which is marketed by Sanofi.
“US Antidiabetics Drug Market Outlook 2022” report highlights:
- US Diabetes Epidemiology
- US Antidiabetics Market Overview
- Key Marketed Antidiabetic Drugs in US
- US Biosimilar Insulin Market
- US Antidiabetics Drug Market Future Prospects
1. ANTIDIABETICS: REGIMEN FOR DIABETES MELLITUS
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics
2. ANTIQUITY OF MANAGING DIABETES MELLITUS
2.1 Trajectory from Diabetes to Insulin
2.2 Historical En Route towards Oral Diabetic Medication
3. TREATMENTS AVAILABLE FOR DIABETES MELLITUS
3.1 Non-Pharmacological Approaches for Diabetes Mellitus
3.2 Pharmacological Approaches for Diabetes Mellitus
4. CATALOGUING OF ANTIDIABETIC AGENTS
4.1 Antidiabetic: Oral Agents
4.1.1 Biguanides
4.1.2 Thiazolidinediones (TZDs)
4.1.3 Sulfonylureas
4.1.4 Meglitinides
4.1.5 ?- Glucosidase Inhibitors
4.1.6 Dipeptidyl Peptidase-4 Inhibitor
4.1.7 Bile Acid Sequestrants (BAS)
4.1.8 Dopamine Agonist-2
5. ANTIDIABETIC: INJECTABLE DRUGS
5.1 Insulin: A life saving Modality
5.2 Non-Insulin Alternatives for Diabetes Mellitus
6. US DIABETES EPIDEMIOLOGY
6.1 Prevalence of Type 1 & 2 Diabetes
6.2 Economic Burden Associated with Type 1 & 2 Diabetes: Productivity Loss & Medical Bills
7. US ANTIDIABETICS MARKET OVERVIEW
7.1 Antidiabetic Injectable Market Trends in US
7.2 Antidiabetic Oral Drugs Market Trends in US
7.3 Commending Trends of Antidiabetics
8. US: KEY MARKETED ANTIDIABETIC DRUGS
8.1 Insulin Degludec (Tresiba)- Injection
8.2 Insulin Lispro - Injection
8.3 Insulin Inhalation(Afrezza) - Inhalation
8.4 Insulin Glargine (Toujeo) - Injection
8.5 Insulin Glulisine (Apidra) - Injection
8.6 Insulin Aspart (NovoLog) - Injection
8.7 Insulin Detemir (Levemir FlexTouch) - Injection
8.8 Insulin Glargine (Lantus) - Injection
8.9 Insulin Aspart/Insulin Protamine Aspart (NovoLog) - Injection
9. US BIOSIMILAR MARKET: GLARGINE BASAGLAR – THE FIRST “BIOSIMILAR” INSULIN
9.1 Overview
9.2 Impact of Biosimilar Insulin
10. US ANTIDIABETICS DRUG MARKET DYNAMICS
10.1 Accelerative Parameters
10.2 Major Challenges
11. US ANTIDIABETICS DRUG MARKET FUTURE PROSPECTS
12. COMPETITIVE LANDSCAPE
12.1 AstraZeneca
12.2 Bayer
12.3 Boehringer Ingelheim
12.4 Eli-Lilly
12.5 Johnson & Johnson
12.6 Merck
12.7 Novartis
12.8 Novo Nordisk
12.9 Sanofi
12.10 Takeda
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics
2. ANTIQUITY OF MANAGING DIABETES MELLITUS
2.1 Trajectory from Diabetes to Insulin
2.2 Historical En Route towards Oral Diabetic Medication
3. TREATMENTS AVAILABLE FOR DIABETES MELLITUS
3.1 Non-Pharmacological Approaches for Diabetes Mellitus
3.2 Pharmacological Approaches for Diabetes Mellitus
4. CATALOGUING OF ANTIDIABETIC AGENTS
4.1 Antidiabetic: Oral Agents
4.1.1 Biguanides
4.1.2 Thiazolidinediones (TZDs)
4.1.3 Sulfonylureas
4.1.4 Meglitinides
4.1.5 ?- Glucosidase Inhibitors
4.1.6 Dipeptidyl Peptidase-4 Inhibitor
4.1.7 Bile Acid Sequestrants (BAS)
4.1.8 Dopamine Agonist-2
5. ANTIDIABETIC: INJECTABLE DRUGS
5.1 Insulin: A life saving Modality
5.2 Non-Insulin Alternatives for Diabetes Mellitus
6. US DIABETES EPIDEMIOLOGY
6.1 Prevalence of Type 1 & 2 Diabetes
6.2 Economic Burden Associated with Type 1 & 2 Diabetes: Productivity Loss & Medical Bills
7. US ANTIDIABETICS MARKET OVERVIEW
7.1 Antidiabetic Injectable Market Trends in US
7.2 Antidiabetic Oral Drugs Market Trends in US
7.3 Commending Trends of Antidiabetics
8. US: KEY MARKETED ANTIDIABETIC DRUGS
8.1 Insulin Degludec (Tresiba)- Injection
8.2 Insulin Lispro - Injection
8.3 Insulin Inhalation(Afrezza) - Inhalation
8.4 Insulin Glargine (Toujeo) - Injection
8.5 Insulin Glulisine (Apidra) - Injection
8.6 Insulin Aspart (NovoLog) - Injection
8.7 Insulin Detemir (Levemir FlexTouch) - Injection
8.8 Insulin Glargine (Lantus) - Injection
8.9 Insulin Aspart/Insulin Protamine Aspart (NovoLog) - Injection
9. US BIOSIMILAR MARKET: GLARGINE BASAGLAR – THE FIRST “BIOSIMILAR” INSULIN
9.1 Overview
9.2 Impact of Biosimilar Insulin
10. US ANTIDIABETICS DRUG MARKET DYNAMICS
10.1 Accelerative Parameters
10.2 Major Challenges
11. US ANTIDIABETICS DRUG MARKET FUTURE PROSPECTS
12. COMPETITIVE LANDSCAPE
12.1 AstraZeneca
12.2 Bayer
12.3 Boehringer Ingelheim
12.4 Eli-Lilly
12.5 Johnson & Johnson
12.6 Merck
12.7 Novartis
12.8 Novo Nordisk
12.9 Sanofi
12.10 Takeda
LIST OF FIGURES
Figure 1-1: Illustration of the Categories of Diabetes Mellitus
Figure 1-2: Percentage of Different types of Antidiabetics Used
Figure 2-1: Historical Pathway of oral Diabetic Medication
Figure 3-1: Control of Glucose Uptake during Muscle Working
Figure 4-1: Categorization of Oral Antidiabetics Approved in US
Figure 4-2: Chemical Structure of Metformin, Phenformin & Buformin
Figure 4-3: Illustration of the Sub-Categories of Sulfonylureas
Figure 5-1: Mechanism of Insulin in Regulation of Blood Glucose Levels
Figure 5-2: Differences between Diabetes Mellitus 1 & 2 over Insulin
Figure 5-3: Structure of Differentiation of Peptidic Insulin Analogs
Figure 5-4: Demonstration of Action Profiles of Insulin Analogue
Figure 5-5: Activity Profiles of Different Types of Insulin
Figure 5-6: Difference between Lantus & Levemir
Figure 6-1: US: Number of Type 1 Diabetes Incidence (Million), 2016 & 2022
Figure 6-2: US: Number of Type 2 Diabetes Incidence (Million), 2014 - 2022
Figure 6-3: US: Type 1 Diabetes Prevalence Rate (%), 2016 & 2022
Figure 6-4: US: Type 2 Diabetes Prevalence Rate (%), 2014 - 2022
Figure 6-5: US: Diabetes Prevalence Rate among Adults Aged 18+ (%), 2010 - 2016
Figure 6-6: US: Obesity Rate Among Adults Aged 18+ (%), 2010 - 2016
Figure 6-7: US: Percentage of Adults with Obesity by State (%), 2015
Figure 6-8: Illustration of Total Cost of Diabetes Expenditure
Figure 6-9: Annual Average Cost Of Diabetes per Person in US
Figure 6-10: US: Productivity Loss Due To Type 1 Diabetes (US$ Billion), 2014 - 2022
Figure 6-11: US: Productivity Loss Due To Type 2 Diabetes (US$ Billion), 2014 - 2022
Figure 6-12: US: Medical Cost for Type 1 Diabetes (US$ Billion), 2014-2022
Figure 6-13: US: Medical Cost for Type 2 Diabetes (US$ Billion), 2014-2022
Figure 7-1: Overview of Diabetic Drug Market Segmentation
Figure 7-2: US: Antidiabetics Drug Market (US$ Billion), 2014 - 2022
Figure 7-3: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion), 2016
Figure 7-4: US - Percentage of Most Common Class of Antidiabetics Drugs
Figure 7-5: US – Percentage of Generally Prescribed Anti-Diabetic Drugs (%)
Figure 8-1: US - Insulin Degludec (Tresiba) Injection Sales (US$ Million), 2016-2022
Figure 8-2: US -Insulin Lispro Injection Sales (US$ Million), 2016-2022
Figure 8-3: US - Insulin Glargine (Toujeo) Injection Sales (US$ Million), 2016-2022
Figure 8-4: US - Insulin Glulisine (Apidra) Injection Sales (US$ Million), 2016-2022
Figure 8-5: US - Insulin Detemir (Levemir FlexTouch) Injection Sales (US$ Million), 2016-2022
Figure 9-1: Major Accelerative Parameters for Antidiabetic Market in US
Figure 9-2: Estimated Impact of Increasing Trend in Obesity by 2020
Figure 9-3: Estimated Increase in Total Number with Diagnosed Diabetes till 2050
Figure 9-4: Major challenges in Antidiabetics Market
Figure 9-5: Important Challenges with the Use of Insulin
Figure 10-1: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion), 2022
Figure 10-2: Illustration of Antidiabetic Drugs Under Development
Figure 1-1: Illustration of the Categories of Diabetes Mellitus
Figure 1-2: Percentage of Different types of Antidiabetics Used
Figure 2-1: Historical Pathway of oral Diabetic Medication
Figure 3-1: Control of Glucose Uptake during Muscle Working
Figure 4-1: Categorization of Oral Antidiabetics Approved in US
Figure 4-2: Chemical Structure of Metformin, Phenformin & Buformin
Figure 4-3: Illustration of the Sub-Categories of Sulfonylureas
Figure 5-1: Mechanism of Insulin in Regulation of Blood Glucose Levels
Figure 5-2: Differences between Diabetes Mellitus 1 & 2 over Insulin
Figure 5-3: Structure of Differentiation of Peptidic Insulin Analogs
Figure 5-4: Demonstration of Action Profiles of Insulin Analogue
Figure 5-5: Activity Profiles of Different Types of Insulin
Figure 5-6: Difference between Lantus & Levemir
Figure 6-1: US: Number of Type 1 Diabetes Incidence (Million), 2016 & 2022
Figure 6-2: US: Number of Type 2 Diabetes Incidence (Million), 2014 - 2022
Figure 6-3: US: Type 1 Diabetes Prevalence Rate (%), 2016 & 2022
Figure 6-4: US: Type 2 Diabetes Prevalence Rate (%), 2014 - 2022
Figure 6-5: US: Diabetes Prevalence Rate among Adults Aged 18+ (%), 2010 - 2016
Figure 6-6: US: Obesity Rate Among Adults Aged 18+ (%), 2010 - 2016
Figure 6-7: US: Percentage of Adults with Obesity by State (%), 2015
Figure 6-8: Illustration of Total Cost of Diabetes Expenditure
Figure 6-9: Annual Average Cost Of Diabetes per Person in US
Figure 6-10: US: Productivity Loss Due To Type 1 Diabetes (US$ Billion), 2014 - 2022
Figure 6-11: US: Productivity Loss Due To Type 2 Diabetes (US$ Billion), 2014 - 2022
Figure 6-12: US: Medical Cost for Type 1 Diabetes (US$ Billion), 2014-2022
Figure 6-13: US: Medical Cost for Type 2 Diabetes (US$ Billion), 2014-2022
Figure 7-1: Overview of Diabetic Drug Market Segmentation
Figure 7-2: US: Antidiabetics Drug Market (US$ Billion), 2014 - 2022
Figure 7-3: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion), 2016
Figure 7-4: US - Percentage of Most Common Class of Antidiabetics Drugs
Figure 7-5: US – Percentage of Generally Prescribed Anti-Diabetic Drugs (%)
Figure 8-1: US - Insulin Degludec (Tresiba) Injection Sales (US$ Million), 2016-2022
Figure 8-2: US -Insulin Lispro Injection Sales (US$ Million), 2016-2022
Figure 8-3: US - Insulin Glargine (Toujeo) Injection Sales (US$ Million), 2016-2022
Figure 8-4: US - Insulin Glulisine (Apidra) Injection Sales (US$ Million), 2016-2022
Figure 8-5: US - Insulin Detemir (Levemir FlexTouch) Injection Sales (US$ Million), 2016-2022
Figure 9-1: Major Accelerative Parameters for Antidiabetic Market in US
Figure 9-2: Estimated Impact of Increasing Trend in Obesity by 2020
Figure 9-3: Estimated Increase in Total Number with Diagnosed Diabetes till 2050
Figure 9-4: Major challenges in Antidiabetics Market
Figure 9-5: Important Challenges with the Use of Insulin
Figure 10-1: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion), 2022
Figure 10-2: Illustration of Antidiabetic Drugs Under Development
